1
Stéphane De Lombaert
Raymond F Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen Corporation, Pfizer, Ladas & Parry, January 14, 2003: US06506762 (111 worldwide citation)

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stéphane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines. Pfizer, Neurogen Corporation, Ladas & Parry, May 20, 2003: US06566367 (57 worldwide citation)

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treat ...


3
Stéphane De Lombaert
Raymond F Horvath, Jennifer N Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen Corporation, Pfizer, Ladas & Parry, February 24, 2004: US06696445 (3 worldwide citation)

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY


4

5
Stéphane De Lombaert
Raymond F Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen, Pfizer, Sonia K Guterman, Lawson & Weitzen, July 11, 2006: US07074929

This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula II, IV, V, VII–IX and XI


6

7
Lee Funk
Lee Andrew Funk, Mary Catherine Johnson, Pei Pei Kung, Zhongxiang Zhou: Amide resorcinol compounds. Pfizer, Pfizer, August 27, 2009: US20090215742-A1

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.


8
Qi Bin Bao, Paul A Higham: Hydrogel intervertebral disc nucleus. Pfizer Hospital Products Group, Peter C Richardson, Lawrence C Akers, Raymond W Augustin, September 10, 1991: US05047055 (684 worldwide citation)

A prosthetic nucleus for a vertebral disc is made of a hydrogel material. The hydrogel prosthetic nucleus has a shape generally conforming to the natural nucleus pulposus. The hydrogel has a water content of at least 30% and has a compressive strength of 4MNm.sup.-2 or greater. When the hydrogel mat ...


9
Paul A Armond, Peter M Orr: Protogyny in Zea mays. Dekalb Pfizer Genetics, Charles J Knuth, Peter C Richardson, Robert F Sheyka, June 30, 1987: US04677246 (661 worldwide citation)

Novel protogynous Zea mays plants are disclosed, including a novel protogynous inbred line, LALGI. Also disclosed are a process to produce such Zea mays plants and hybrids resulting from crossing such plants with other inbred lines such as Iowa Stiff Stalk Synthetic Lines.


10
Qi Bin Bao, Paul A Higham: Hydrogel bead intervertebral disc nucleus. Pfizer Hospital Products Group, Peter C Richardson, Lawrence C Akers, Raymond W Augustin, March 9, 1993: US05192326 (596 worldwide citation)

A prosthetic nucleus for implantation in the disc space after removal of a damaged or degenerated nucleus is formed from a multiplicity of hydrogel beads having a water content of at least 30%. The beads are covered by a semi-permeable membrane. The membrane has porosity less than the size of the be ...



Click the thumbnails below to visualize the patent trend.